Skip to main content

Table 4 Table of 3-point MACE for CVOT studies to date.

From: Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

 

Antidiabetic drug

3P-MACE hazard ratio (HR)

p value

PROactive

Pioglitazone

0.84 (95% CI 0.72–0.98)

0.02

ORIGIN

Insulin glargine

1.02 (95% CI 0.94–1.11)

NS

SAVOR

Saxagliptin

1.00 (95% CI 0.89–1.12)

NS

EXAMINE

Alogliptin

0.96 (95% CI 0.80–1.15)

NS

ELIXA

Lixisenatide

1.02 (95% CI 0.89–1.17)

NS

TECOS

Sitagliptin

0.98 (95% CI 0.89–1.08)

NS

EMPA-REG OUTCOME®

Empagliflozin

0.86 (95% CI 0.74–0.99)

0.038

LEADER®

Liraglutide

0.87 (95% CI 0.78–0.97)

0.01

SUSTAIN™-6

Semaglutide

0.74 (95% CI 0.58–0.95)

< 0.001a

CANVAS-program

Canagliflozin

0.86 (95% CI 0.75–0.97)

0.02

  1. This is not a head-to-head comparison
  2. CVOT cardiovascular outcomes trial, MACE major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke), NS not significant
  3. aSUSTAIN™-6 was a non-inferiority study, and testing for superiority was not a pre-specified endpoint